<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50-ijerph-17-01395">
 <label>50.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Karo</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Kohlenberg</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Hollo</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Duarte</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Fiebig</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Jackson</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Kearns</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ködmön</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Korzeniewska-Kosela</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Papaventsis</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: Analysis of European surveillance data, 2002 to 2014</article-title>
  <source>Eur. Surveill.</source>
  <year>2019</year>
  <volume>24</volume>
  <fpage>1800392</fpage>
  <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2019.24.12.1800392</pub-id>
 </element-citation>
</ref>
